Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure
- 16 July 2003
- journal article
- website
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 33 (8) , 648-656
- https://doi.org/10.1046/j.1365-2362.2003.01187.x
Abstract
Background Progression of heart failure is associated with interstitial changes in the heart and in areas distant from the heart. Enhanced expression of metalloproteinases 2 and 9 and of metalloproteinases tissue inhibitors 1 and 2 have been found in ventricular tissue of patients with heart failure. Our aim was to determine whether increased activity of metalloproteinase‐2, metalloproteinase‐9 and of metalloproteinases tissue inhibitor‐1 and metalloproteinases tissue inhibitor‐2 were also present in plasma of patients with heart failure.Design Levels of metalloproteinase‐2, metalloproteinase‐9 and of metalloproteinase tissue inhibitor‐1 and metalloproteinases tissue inhibitor‐2 were measured in venous blood of 51 patients with heart failure, and were compared with levels of 52 control subjects. Samples collected from patients and control subjects were assayed for gelatinolytic activity (zymography) and for protein levels.Results Compared with the control subjects, the patients with heart failure had a significant increase in activity levels (mean ± SE, ng mL−1) of prometalloproteinase‐9 (95·1 ± 11·2 and 38·9 ± 4·5*), activ. metalloproteinase‐9 (18·4 ± 2·5 and 10·9 ± 1·3*), and of prometalloproteinase‐2 (571·4 ± 26·1 and 456·8 ± 21·1*) (respectively: patients and control sub jects; *P < 0·05). Metalloproteinases tissue inhibitor‐1, but not metalloproteinases tissue inhibitor‐2 protein values were higher in the patients. Among the patients, clinical status and New York Heart Association (NYHA) class did not correlate with the metalloproteinase concentrations. Positive correlations with left ventricular volumes, and negative correlations with lipid values were obtained for prometalloproteinase‐2; positive correlations with total number of white cells and neutrophils were obtained for prometalloproteinase‐9; and positive correlations with lactate dehydrogenase, serum fibrinogen, aspartate transaminases were found for activ. metalloproteinase‐9.Conclusions Regardless of the clinical phase of heart failure, elevated levels of activity and of circulating metalloproteinase protein levels suggest the presence of persistent extracellular remodeling in patients with heart failure.Keywords
This publication has 31 references indexed in Scilit:
- Plasma Matrix Metalloproteinase-9 as a Marker of Blood Stasis in Varicose VeinsCirculation, 2002
- Factor Xa Releases Matrix Metalloproteinase-2 (MMP-2) From Human Vascular Smooth Muscle Cells and Stimulates the Conversion of Pro–MMP-2 to MMP-2Circulation Research, 2002
- Matrix MetalloproteinasesCirculation Research, 2002
- Shedding of the Matrix Metalloproteinases MMP-2, MMP-9, and MT1-MMP as Membrane Vesicle-Associated Components by Endothelial CellsThe American Journal of Pathology, 2002
- Cytokines and Cytokine Receptors in Advanced Heart FailureCirculation, 2001
- Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failureInternational Journal of Cardiology, 2000
- Association of serum sialic acid and MMP‐9 with lipids and inflammatory markersEuropean Journal of Clinical Investigation, 2000
- Extracellular Matrix-Driven Matrix Metalloproteinase Production in Endothelial CellsTrends in Cardiovascular Medicine, 1999
- Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human HeartCirculation, 1996
- Human neutrophil gelatinase: A marker for circulating blood neutrophils. Purification and quantitation by enzyme linked immunosorbent assayEuropean Journal of Haematology, 1992